David Stock

VP, Biostatistics at Biohaven Pharmaceuticals

Dr. Stock has more than 20 years of experience developing biostatistical solutions for the pharmaceutical industry. David came to Biohaven from Bristol-Myers Squibb (BMS), where he was the Therapeutic Area Lead for Genetically Defined Diseases. While at BMS, David also served as Statistical Lead for late stage HIV compounds, and Head of Nonclinical Biostatistics. In addition, he oversaw the response-adaptive clinical trial which established the efficacy of Rimegepant. David’s publication record includes articles on evaluating the value of backup compounds in drug development, large sample inference techniques for high throughput screening, and numerous clinical trials. He is currently Co-chair of the Council of Biopharmaceutical Statistics, former Chair of the Quantitative Sciences in the Pharmaceutical Industry (QSPI) Committee and was an elected member of the PhRMA Biostatistics and Data Management Technical Group (BDMTG). David first entered the pharmaceutical industry from Brookhaven National Laboratory (BNL) where he worked on projects for the Nuclear Regulatory Commission and the Department of Energy. David received his Ph.D. in Applied Mathematics, with a specialization in Statistics, at the State University of New York at Stony Brook.

Timeline

  • VP, Biostatistics

    Current role

View in org chart